Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Silexion Therapeutics Corp
Silexion Therapeutics Announces Exercise of Warrants
September 29, 2026
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
September 28, 2026
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
September 9, 2026
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
August 4, 2026
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
July 29, 2026
Silexion Therapeutics Receives Approval from Germany’s BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
June 23, 2026
Silexion Therapeutics to Attend BIO International Convention 2026
June 16, 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
May 26, 2026
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
1
2
Next Page
→